Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
Healthcare
$10.17 -1.58%
-$0.19 today
- Market cap
- $857.87M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
52W Low $3.55High $26.95
Volume 0.93M
Average 1.49M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$42.97M
FY 2025 · Annual
Net Income
-$15.28M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 105K |
| Gross Profit | 0 | 0 | 0 | 0 | (105K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Selling, General & Admin | 9.52M | 8.1M | 6.88M | 8.16M | 9.25M |
| Operating Expenses | 38.63M | 32.57M | 23.41M | 27.55M | 42.87M |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| EBITDA | (42.77M) | (40.94M) | (26.88M) | (62.21M) | (15.18M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (38.63M) | (32.57M) | (23.41M) | (27.55M) | (42.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 654K | 1.58M | 1.82M | 2.51M |
| Interest Expense | 15K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (4.61M) | (8.74M) | (3.62M) | (34.75M) | 27.69M |
| Income Before Tax | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.03) | (0.89) | (0.56) | (1.02) | (0.19) |
| EPS (Diluted) | (1.03) | (0.89) | (0.56) | (1.02) | (0.53) |
| 41.85M | 46.55M | 48.03M | 60.99M | 78.96M | |
| 41.85M | 46.55M | 48.03M | 60.99M | 79.74M |
CRVS Earnings Waterfall · TTM
NASDAQ:CRVS · Revenue to Net Income
Key Ratios
EPS$-0.55
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-15.3
P/S Ratio0.0
Analysis
$0 of revenue converted into -$44.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.55, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G | SC 13G filing | Aug 7, 2026 |
How much revenue does CRVS generate?
Corvus Pharmaceuticals, Inc. (CRVS) reported $0.00 of revenue in fiscal 2025.
Is CRVS profitable?
Corvus Pharmaceuticals, Inc. (CRVS) reported -$15.28M of net income.
Continue the stock analysis
Jump to another research area for this company.